Patents by Inventor Yoshiro Kitahara

Yoshiro Kitahara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220249592
    Abstract: Agents containing ?-glutamyl peptide can prevent a decline in muscle quality and improve muscle quality even when exercise is limited, and further, can effectively enhance the effect of exercise even when the exercise is of a level free of undue efforts.
    Type: Application
    Filed: April 22, 2022
    Publication date: August 11, 2022
    Applicant: AJINOMOTO CO., INC.
    Inventors: Kyoko MIURA, Yoshiro KITAHARA, Haruka OHASHI
  • Publication number: 20220088111
    Abstract: Peptides consisting of the amino acid sequence of any of LIVTQTMKGL (SEQ ID NO: 1), LIVTQTMKG (SEQ ID NO: 2), LIVTQTMK (SEQ ID NO: 3), IVTQTMKGL (SEQ ID NO: 4), IVTQTMKG (SEQ ID NO: 5), and VTQTMKGL (SEQ ID NO: 6) are useful for improving intestinal barrier function, for suppressing blood glucose elevation, for improving insulin sensitivity, for promoting FGF21 secretion, for suppressing stress or protecting nerves, or for reducing fatigue.
    Type: Application
    Filed: December 10, 2021
    Publication date: March 24, 2022
    Applicant: AJINOMOTO CO., INC.
    Inventors: Yoshiro KITAHARA, Yoriko OKAMATSU, Kazutaka SHIMBO, Naoko ARASHIDA, Ayaka SHIRASAWA
  • Publication number: 20210308084
    Abstract: Muscle quality-improving agents containing one or more selected from the group consisting of isoleucine, glycine, and cystine can prevent a decline in muscle quality, improve muscle quality even when exercise is limited, and can effectively enhance the effect of exercise even when the exercise is of a level free of undue efforts.
    Type: Application
    Filed: June 16, 2021
    Publication date: October 7, 2021
    Applicant: AJINOMOTO CO., INC.
    Inventors: Kyoko MIURA, Mai NAKAZAWA, Yoshiro KITAHARA
  • Publication number: 20200129458
    Abstract: Compounds represented by formula (I): wherein each symbol is as defined in the present specification, or a salt thereof are useful for the prophylaxis or treatment of diabetes and obesity, and diseases related thereto.
    Type: Application
    Filed: December 27, 2019
    Publication date: April 30, 2020
    Applicant: AJINOMOTO CO., INC.
    Inventors: Tomohiro FUJII, Koji Ohsumi, Seiji Kitajima, Yoshiro Kitahara
  • Publication number: 20190022039
    Abstract: Compounds represented by formula (I): wherein each symbol is as defined in the present specification, or a salt thereof are useful for the prophylaxis or treatment of diabetes and obesity, and diseases related thereto.
    Type: Application
    Filed: September 27, 2018
    Publication date: January 24, 2019
    Applicant: AJINOMOTO CO., INC.
    Inventors: Tomohiro FUJII, Koji OHSUMI, Seiji KITAJIMA, Yoshiro KITAHARA
  • Patent number: 9907766
    Abstract: Sweetness receptor antagonists represented by formula (I): wherein each symbol is described herein, are useful for the prophylaxis or treatment of metabolic syndrome, diabetes, obesity and the like.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: March 6, 2018
    Assignee: AJINOMOTO CO., INC.
    Inventors: Yoshiro Kitahara, Koji Ohsumi, Seiji Kitajima, Shimpei Ogawa
  • Publication number: 20170101372
    Abstract: Sweetness receptor antagonists represented by formula (I): wherein each symbol is described herein, are useful for the prophylaxis or treatment of metabolic syndrome, diabetes, obesity and the like.
    Type: Application
    Filed: December 23, 2016
    Publication date: April 13, 2017
    Applicant: AJINOMOTO CO., INC.
    Inventors: Yoshiro KITAHARA, Koji OHSUMI, Seiji KITAJIMA, Shimpei OGAWA
  • Patent number: 9150505
    Abstract: An object is to provide a CaSR agonist agent that has excellent CaSR agonist effects, and particularly, a pharmaceutical product that can prevent or remedy diabetes or obesity by the effect of CaSR activation. The aforementioned object is achieved by a composition that contains a compound represented by the following General Formula (I) or a salt thereof (refer to the Description for the definitions of the symbols used in the formula).
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: October 6, 2015
    Assignee: AJINOMOTO CO., INC.
    Inventors: Reiko Yasuda, Yuzuru Eto, Yoshiro Kitahara
  • Publication number: 20130072491
    Abstract: An object is to provide a CaSR agonist agent that has excellent CaSR agonist effects, and particularly, a pharmaceutical product that can prevent or remedy diabetes or obesity by the effect of CaSR activation. The aforementioned object is achieved by a composition that contains a compound represented by the following General Formula (I) or a salt thereof (refer to the Description for the definitions of the symbols used in the formula).
    Type: Application
    Filed: August 31, 2012
    Publication date: March 21, 2013
    Applicant: Ajinomoto Co., Inc.
    Inventors: Reiko YASUDA, Yuzuru Eto, Yoshiro Kitahara
  • Publication number: 20090247636
    Abstract: The present invention aims to provide a more effective gastric emptying suppressant and food intake suppressant, wherein the solving means are a gastric emptying suppressant containing 4-hydroxyisoleucine or a salt thereof and a food intake suppressant containing 4-hydroxyisoleucine or a salt thereof.
    Type: Application
    Filed: April 13, 2009
    Publication date: October 1, 2009
    Applicant: AJINOMOTO CO., INC.,
    Inventors: Atsushi KONISHI, Ikumi Ishibashi, Yoshiro Kitahara, Kyoko Miura, Sachiko Narasaka
  • Publication number: 20090176835
    Abstract: The present invention provides a pharmaceutical composition for suppression of the expression of ATP citrate lyase, which contains a compound that suppresses the expression of ATP citrate lyase by the in vivo administration. The compounds suppress the expression of ATP citrate lyase by the in vivo administration include insulin secretagogues such as nateglinide. This pharmaceutical composition is effective in preventing, improving and treating metabolic syndrome, in particular, liver disorders related to abnormal lipid metabolism such as fatty liver and NASH.
    Type: Application
    Filed: March 5, 2009
    Publication date: July 9, 2009
    Applicant: Ajinomoto Co., Inc.
    Inventors: Yoshiro KITAHARA, Tomohisa OKUTSU, Akira MITSUI, Akira OKANO
  • Publication number: 20070275999
    Abstract: The present invention provides a pharmaceutical composition containing a hypoglycemic agent(s) as an active ingredient for improving or treating impaired glucose tolerance, borderline diabetes, insulin resistance or hyperinsulinemia. The present invention further provides a pharmaceutical composition for preventing or delaying the progression from impaired glucose tolerance, borderline diabetes, insulin resistance or hyperinsulinemia to diabetes mellitus or metabolic syndromes; or the progression to the state easy to develop macrovascular disorders, cardiovascular events or ischemic heart disease.
    Type: Application
    Filed: July 31, 2007
    Publication date: November 29, 2007
    Applicant: Ajinomoto Co., Inc.
    Inventors: Yoshiro Kitahara, Kyoko Miura
  • Publication number: 20070049535
    Abstract: The present invention provides a novel agent for the prophylaxis or treatment of diabetic complications. Specifically, the present invention provides an agent for the prophylaxis or treatment of diabetic complications, which contains, as an active ingredient, an oligopeptide containing at least two amino acid residues having an amino group or a guadinino group in the side chain, and which has AGE2 production inhibitory action and AGE2 blood concentration reduction promoting action.
    Type: Application
    Filed: September 26, 2006
    Publication date: March 1, 2007
    Inventors: Yoshiro Kitahara, Masayoshi Takeuchi
  • Publication number: 20050096367
    Abstract: The present invention provides a pharmaceutical composition for suppression of the expression of ATP citrate lyase, which contains a compound that suppresses the expression of ATP citrate lyase by the in vivo administration. The compounds suppress the expression of ATP citrate lyase by the in vivo administration include insulin secretagogues such as nateglinide. This pharmaceutical composition is effective in preventing, improving and treating metabolic syndrome, in particular, liver disorders related to abnormal lipid metabolism such as fatty liver and NASH.
    Type: Application
    Filed: November 29, 2004
    Publication date: May 5, 2005
    Inventors: Yoshiro Kitahara, Tomohisa Okutsu, Akira Mitsui, Akira Okano
  • Publication number: 20030073729
    Abstract: The present invention relates to methods for the prophylactic or therapeutic treatment in a subject from complications relating to diabetes mellitus using at least a postprandial blood sugar lowering agent and/or methods for the prophylactic or therapeutic treatment of neuropathy in a subject.
    Type: Application
    Filed: September 17, 2002
    Publication date: April 17, 2003
    Applicant: AJINOMOTO CO. INC
    Inventors: Yoshiro Kitahara, Kyoko Miura
  • Patent number: 5525335
    Abstract: Wound healing agents (especially a cicatricial contracture preventing agent, a wound protective or coating agent and a hemostatic agent) containing transglutaminaseas an active ingredient, which are novel and excellent wound healing agents with which cicatricial contracture prevention, wound protection or coating and blood stanching can be made simply and easily.
    Type: Grant
    Filed: December 21, 1993
    Date of Patent: June 11, 1996
    Assignee: Ajinomoto Co., Inc.
    Inventors: Yoshiro Kitahara, Tsuyoshi Ohsumi, Yuzuru Eto, Satoshi Takano